FDA Approval Insights: Avapritinib in Indolent Systemic Mastocytosis

Season 9 Episode 9  ·  Jul 10, 2023, 06:30 PM

Headliner
Share
Subscribe

Dr Gotlib discusses the significance of the FDA approval of avapritinib in indolent systemic mastocytosis, key findings from the PIONEER trial, and the quality of life benefits that avapritinib provides for patients in this population.

Share
Subscribe
Next
Lunning and Abramson Spotlight Developments and Challenges in LBCL Research and Management
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air